PCSK9 Inhibitors ' Cost Effectiveness Questioned Again (FREE)

By Joe Elia Edited by Susan Sadoughi, MD PCSK9 inhibitors, monoclonal antibodies that dramatically lower LDL levels, are priced far higher than what society is willing to pay for their benefits, according to reports and commentary in JAMA Cardiology.One study used earlier work …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news